Nanostructured Lipid Carrier: Optimization, In-vitro, In-vivo Evaluation of Nanocarrier Gel
Abstract
Pharmaceutical gels are semisolid dosage form designed for application on to the skin mucus membrane and wounds. They are versatile patient friendly formulations that can deliver drugs systemically and locally. Nanostructured lipid carriers loaded gel was prepared for making the topical delivery more effective. Optimized formulation of nanostructured lipid carriers loaded gel exhibits higher in-vitro controlled release pattern as compared to marketed formulation and nanocarrier suspension. In vivo pharmacodynamic studies shows good results of wound contraction studies. These findings suggest that nanostructured lipid carriers loaded gel can serve as a promising drug delivery system to overcome the limitations of conventional formulations and provides better therapeutic outcomes
Downloads
Metrics
References
Basra M. K. A., Shahrukh M., Burden of skin diseases, Expert rev., 2009, 9, 271-283.
Diepgen T. L., Occupational skin diseases, J. Dtsch. Dermatol. Ges., 2012, 5, 297-315.
Ruocco E., Donnarumma G., Baroni M., Tufano A., Bacterial and viral skin diseases, Dermatol. Cling., 2007, 25, 663-676.
Noble W. C., Skin bacteriology and role of staphylococcus aureus in infection, Br. J. Dermatol., 1998, 139, 9-12.
Gupta A. K., MacLeod M. A., Foley K. A., Gupta G., Friedlander S. F., Fungal skin infections, Pediatr. Rev., 2017, 38, 8-21.
Borgers M., Degreef H., Cauwenbergh G., Fungal infections of the skin: infection process and antimycotic therapy, Curr. drug targets, 2005, 6, 849-862.
Rinaldi M. G., Dermatophytosis: epidemiological and microbiological update, J. Am. Acad. Dermatol., 2000, 43, S120-4.
Lipner S. R., Scher R. K., Onchomycosis clinical overview and diagnosis, J. Am. Acad. Dermatol., 2019, 80, 835-851.
Buhse L., KolinskiR., Westenberger B., Wokovich A., Spencer J., Chen C. W. et. al., 2005, Topical drug classification, Int. J. Pharm., 2005, 295, 101-112.
Rehman K., zulfakar M. H., Recent advances in gel technologies for topical and transdermal drug delivery, Drug. Dev. Ind. Pharm., 2014, 40, 433-440.
Maver U., Godec A., Bele M., Planinsek O., Gaberscek M., Srcic S., et. al., Novel hybrid silica xerogel for stabilization and controlled release of drug, Int. J. Pharm., 2007, 330, 164-174.
Gausia B. S., Madhusudan C. C., Kumar V. V., Pavithra B., Akhila B., Gayathri C., et. al., A review on emulgels- a novel approach for topical drug delivery, Asian J. Pharm Res Dev., 2019, 7, 70-77.
Sanclemente G., Burgos C., Nova J., Hernandez F., Gonzalez C., Reyes M. I., et. al. The impact of skin diseases on quality of life: a multicenter study, Actas dermosifiliogr., 2017, 108, 244-252.
Mekkawy A., Fathy M., El-shanawany S., Formulation and in vitro evaluation of fluconazole topical gel, Br.J. Pharm. Res., 2013, 3, 293-313.
Bachhav Y. G., Patravale V. B., Formulation of meloxicam gel for topical application: in vitro and in vivo evaluation, Acta pharm., 2010, 60, 153-163.
Singh M. P., Nagori B. P., Shaw N. R., Tiwari M., Jhanwar B., Formulation development and evaluation of topical gel formulations using different gelling agents and its comparison with marketed gel formulation, Int. J. pharm. erud., 2013, 3, 1-10.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pragati Khare, Janki Prasad Rai
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
